Bausch+Lomb Results Presentation Deck
Segment Reported Revenue
Vision Care ³
Contact Lens Revenue
Consumer Revenue
Total Revenue
Surgical²
Implantables Revenue
Equipment Revenue
Consumables Revenue
Total Revenue
Pharmaceuticals 3
Total Revenue
BAUSCH+ LOMB
3Q23
$228M
$420M
$648M
3Q23
$45M
$47M
$93M
$185M
3Q23
$174M
3Q22
$222M
$375M
$597M
3Q22
$45M
$42M
$85M
$172M
3Q22
$173M
Reported Change
3%
12%
9%
Reported Change
0%
12%
9%
8%
Reported Change
1%
Constant Currency
Change¹
5%
14%
11%
Constant Currency
Change¹
(2%)
10%
8%
6%
Constant Currency
Change¹
1%
1. This is a non-GAAP measure or ratio. See Slide 1 and this Appendix for further information on non-GAAP measures and ratios.
2. As of the first quarter of 2023, certain products were recategorized across the consumables, implantables and equipment product categories. This change was made as management believes this better aligns these products in their respective
categories. Prior period presentations of product categories have been conformed to current product category structure to allow investors to evaluate results between periods on a consistent basis.
3. Effective in the first quarter of 2023, certain products historically included in the reported results of the Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in the reported
results of the Vision Care segment are now included in the reported results of the Pharmaceuticals segment. Management believes these movements are necessary in order to better align these products with the groupings of similar products.
The net impact of these product movements was not material to the periods presented. Prior period presentations of segment revenues have been conformed to the current segment reporting structure.
25View entire presentation